Hang Seng Index Company: Focus on three major development directions in the future, expand the management scale of tracking technology-related index assets.

The CEO of Hang Seng Index Company, Stephanie Ng, stated that looking back at 2025, the atmosphere in the Hong Kong stock market was very enthusiastic. By December 31st of last year, the Hang Seng Index achieved its best performance since 2017, with a year-on-year increase of 27.8%. The total value of assets under management (AUM) linked to the Hang Seng Index series reached approximately $117.7 billion. The Hang Seng Biotechnology Index achieved its highest annual increase since its launch in 2025, with a year-on-year increase of 64.5%. Ng pointed out three major development directions for the future, including consolidating the market leadership in the technology and biotechnology sectors, expanding the asset management scale tracking technology-related indices, continuously expanding the biotechnology index, and supporting the development of diversified products; actively promoting product innovation, exploring more applications of artificial intelligence in business, launching products that closely follow market trends and demands, and developing cross-market indices; and continuing to promote business development in overseas markets to help global investors seize investment opportunities in Hong Kong and mainland China. When asked about a timetable for the inclusion of 100 constituent stocks in the Hang Seng Index, Ng stated that the relevant process is ongoing and no timetable has been set. Joyce Lam, the Product Director of Hang Seng Index Limited, stated that the Hang Seng Biotechnology Index achieved a increase of over 60% last year, outperforming the broader market and other mainstream indices, including its three flagship indices. This reflects the high level of attention the capital market has towards the biotechnology sector. She also mentioned three structural drives that promote the development of the healthcare industry: aging population, rising disposable income, and potential for medical spending. Additionally, she noted that the activity level of IPOs in the healthcare industry has noticeably increased. Lam mentioned that in order to help investors further grasp growth opportunities in the technology and biotechnology sectors, Hang Seng Index Company launched the "Hang Seng Dual Technology Index" in January this year. The new index is used to measure the overall performance of technology and biotechnology companies in the Hong Kong stock market, combining these two themes into a single benchmark to reflect both their market value differences and representativeness, with 75% of the weight allocated to the Hang Seng Technology Index and 25% to the Hang Seng Biotechnology Index.